Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17916301 | 0.87 | GABRA1 (0.39) | GABRA1GABRB2NOS3NOS1NOS2 | |
| SCHEMBL4575378 | 0.85 | CNR1 (0.38) | GABRA1GABRB2NOS3NOS1NOS2 | |
| SCHEMBL21779670 | 0.83 | GABRA1 (0.34) | GABRA1GABRB2NOS3NOS1NOS2 | |
| SCHEMBL10492672 | 0.80 | CNR1 (0.38) | GABRA1GABRB2NOS3NOS1NOS2 | |
| SCHEMBL5164118 | 0.80 | PTGS2 (0.48) | GABRA1GABRB2NPC1RAB9ACNR1 | |
| SCHEMBL16955099 | 0.80 | OPRM1 (0.33) | GABRA1GABRB2CTSSCTSKCNR1 | |
| SCHEMBL18949819 | 0.78 | GABRA1 (0.33) | GABRA1GABRB2NOS3NOS1NOS2 | |
| SCHEMBL16958115 | 0.77 | GABRA1 (0.34) | GABRA1GABRB2CTSSCTSKCNR1 | |
| SCHEMBL16958684 | 0.76 | GABRA1 (0.33) | GABRA1GABRB2CTSSCTSKNPC1 | |
| SCHEMBL16958637 | 0.76 | CTSS (0.33) | GABRA1GABRB2CTSSCTSKOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3245213-B1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL MYERS SQUIBB CO (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20180079781-A1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-22 | — | — | US | disclosed |
| US-20170233436-A1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL-MYERS SQUIBB COMPANY | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233436-A1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | GABRA1, GABRA3, GABRA2 | GABRA1 1/4885GABRB2 12/4885CTSS 4381/4885 |
| US-20180079781-A1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | GABRA1, GABRA3, GABRA2 | GABRA1 1/4885GABRB2 12/4885CTSS 4381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.